Immunovant

Register to learn more about a Phase 3 clinical trial in people with mild to severe #MyastheniaGravis: https://lnkd.in/eyjjUAEa. This virtual MedscapeLIVE event will take place on Wednesday, December 10, 12:00-12:30pm ET and feature Richard Nowak, MD, MS, Director of Neuromuscular Research, Yale School of Medicine. This program will provide an overview of the Propel clinicial trial of IMVT-1402*, including the primary objective, study design, eligibility criteria, and opportunities for referring patients. *IMVT-1402 is an investigational drug not approved for use by any regulatory authority in any jurisdiction. #InvisibleDisability #AutoImmuneDisease #autoimmune #PatientFirst #healthcare #ClinicalTrial #MedscapeLive #Medcomms #Medscape

We’re excited to discuss and learn more about the complex and variable needs of those living with #MyastheniaGravis at Myasthenia Gravis Association’s Annual Meeting this year: https://lnkd.in/eUaqsFpY And, for those unable to attend in person in Kansas City, there’s also a virtual option! #InvisibleDisability #AutoImmuneDisease #autoimmune #PatientFirst #healthcare #MGstrong #MGAcommunity #MGA2025

We’re excited to connect at #AANEM2025 (booth 108)! “Every conversation is a meaningful step forward in our collective effort to improve the lives of patients facing challenging diseases like Myasthenia gravis (MG) and CIDP,” says Jorge. And with a view of what’s ahead, join Richard Nowak, MD, MS, Assistant Professor of Neurology at Yale University to learn more about our ongoing Phase 3 study in MG: https://lnkd.in/esF5Y85z #InvisibleDisability #AutoImmuneDisease #neuromuscular #PatientFirst #healthcare #MyastheniaGravis #CIDP #ChronicInflammatoryDemyelinatingPolyneuropathy American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)

Join Dr. Lupo in a MedscapeLIVE event to learn more about the pathophysiology of Graves’ disease on Oct. 28th from Noon-12:30 PM ET: https://lnkd.in/g6pggWDR This program will also provide an overview of the FORWARD and FORWARD2 trials, including the primary objective, study design, eligibility criteria, and opportunities for patient referrals. #GravesDisease #InvisibleDisability #AutoImmuneDisease #autoimmune #PatientFirst #healthcare #thyroid #ClinicalTrial #Medscape #MedscapeLive #MedComms

Andrea is a social person, but after being diagnosed with Graves’ disease (GD) in 2016, she initially ”became like a hermit,” isolating herself from friends and family. GD can sometimes make daily life feel daunting – impacting your relationships, work life, and social activities. #GravesDisease #InvisibleDisability #AutoImmuneDisease #autoimmune #PatientFirst #healthcare #thyroid

"I had a conversation with a young couple at GBS|CIDP Foundation International’s Symposium; the wife had been diagnosed with CIDP after a lengthy process of tests. I got a sense of how receiving a rare disease diagnosis can be overwhelming for a family, and with few physicians experienced in these conditions, how families can often struggle to find clear answers. For me, it really brings home why our ongoing clinical research is so important." - Ian Gourley, VP, Clinical Development at Immunovant Also pictured: Yuriy Edwards, Senior Medical Director (left) and Kristen McCarville, Director, Medical Science Liaison (right) To learn more about #CIDP and why it can be difficult to diagnose, visit: https://lnkd.in/ed2x_QfJ #autoimmune #AutoimmuneDisease #PatientFirst #InvisibleDisability #RareAutoimmuneDisease #GBSCIDPsymposium #ChronicInflammatoryDemyelinatingPolyneuropathy